Physician Views: Oncologists react to approval of Zarxio - the first US biosimilar

Physician Views: Oncologists react to approval of Zarxio - the first US biosimilar

Code: FW-20150303 | Published: Mar-2015 | Pages: - | FirstWord
Price :
$695.00
USD

* Required Fields

$695.00

Details






Following unanimous recommendation from the FDAs Oncologic Drugs Advisory Committee (ODAC) in mid-January, FDA approval for Novartis Zarxio - announced on Friday - came as little surprise (ViewPoints: Approval of the first US biosimilar - the key questions).

Approval does highlight, however, a number of regulatory factors that are likely to play a role in shaping how Zarxio - a biosimilar version of Amgens Neupogen - will be used by physicians.

As FirstWord discusses in more depth here, the FDA has approved Zarxio with a unique international non-proprietary name (INN). Use of an INN that adds the sndz suffix to filgrastim - a placeholder approach according to the FDA, but also a clear signpost of how the administration is thinking, suggest commentators - is beneficial for Amgen (and potentially other branded manufacturers), argue analysts, as it acts as a differentiator between brand and biosimilar.

Branded manufacturers have maintained for some time that biosimilar products should have different INNs to the originator product, while Novartis told FirstWord last week that they believe Zarxio should share an identical INN (i.e. filgrastim) with Neupogen.

A more positive development for biosimilar developers is the FDAs approved labelling for Zarxio, which is very similar to that for Neupogen and emphasises innovator data rather than data supporting biosimilarity (indeed, the label contains no reference to biosimilar). As expected, following the ODAC meeting, Zarxio has also been approved for each of the five indications that Neupogen is authorised for. FirstWord polled US-based oncologists on this issue, among others, following the ODAC meeting in January (see Physician Views Poll Results: Positive FDA sentiment for biosimilar Neupogen shared by oncologists).

While Zarxio is a trailblazer in the US biosimilars market, there remains room for further advancement on the regulatory front. The FDA was keen to stress on Friday that Novartis product has been approved as a biosimilar, but not one that is currently approved as being interchangeable with Neupogen. It has been suggested that Novartis will submit an application to support interchangeability status at a later date, which could clearly have profound implications with how Zarxio is used.








With Zarxio now approved, we are polling US-based oncologists this week to gauge commercial implications associated with the FDAs labelling for the product. Specifically we are asking them



Sandozs Zarxio has been approved with the international non-proprietary name (INN) filgrastim-sndz. Do you think this is an effective naming convention?
- Not at all effective
- Slightly effective
- Moderately effective
- Very effective
- Extremely effective

Do you think that use of this biosimilar naming convention - i.e. inclusion of a unique suffix in addition to the originator INN - will have a negative impact on oncologist usage of Zarxio?
- No negative impact
- Slightly negative impact
- Moderately negative impact
- Very negative impact
- Extremely negative impact

The label for Zarxio looks very similar to that for Neupogen and emphasises innovator data rather than data supporting biosimilarity (indeed the label contains no reference to biosimilar). Adverse events reference clinical trial experience with Neupogen. Is this a positive development?
- Not positive at all
- Slightly positive
- Moderately positive
- Very positive
- Extremely positive

Do you think that this labelling will have a positive impact on oncologist usage of Zarxio?
- No positive impact
- Slightly positive impact
- Moderately positive impact
- Very positive impact
- Extremely positive impact

Assuming that Zarxio later gains FDA approval as an interchangeable biosimilar (it is currently approved as a biosimilar but not interchangeable), would you still prescribe Neupogen and specifically ask that the brand not to be switched in order to prevent substitution?
- Never
- Rarely
- Sometimes
- Often
- Always





Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord

Our Clients